CSI Market
Sign In | Register

Imunon Inc (IMNN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IMNN quarterly Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Imunon Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-14.50
Depreciation & amortization0.29
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.13
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Change In Fair Value Of Common Stock Warrant Liability-
Treasury Stock Contributed To401 K Plan-
Deferred Finance Charges-
Shares Issued In Exchange For Services-
Gain Loss From Valuation Of Earnout Milestone Liability-
Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable-
Shares Issued Upon Vesting Of Stock Awards-
Gain Loss From Change In Earnout Milestone Liability-
Fair Value Of Warrants Issued In Connection With Amendment To Modify Earnout Milestone Payments-
Contract With Customer Liability Revenue Recognized-
Fair Value Of Shares Issued In Exchange For Services0.10
Operating Lease Right Of Use Asset Amortization Expense0.00
Income taxes0.00
Gain (Loss) on Investments0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.52
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.19
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.41
Discontinued operations0.00
Net Cash flow from Operating Activities-13.90
Investing Activities
Capital Expenditures-0.28
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Refund Of Deposit For Letter Of Credit-
Refund Deposit On Corporate Office Lease-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.28
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock17.09
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Warrant Exercises Net Of Issuance Costs-
Payments On Notes Payable Including Endofterm Fees-
Proceeds From Issuance Of Common Stock Upon Conversion Of Stock Warrants-
Proceeds From Issuance Of Common Stock Upon Conversion Of Stock Options-
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options-
Paymentoff Of Loan And Accrued Endofterm Fees-
Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities17.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-14.18
Total Cash Flow2.91
4 historic quarters locked

Sign in to unlock the full Imunon Inc cash flow history.

Sign In Create Free Account

About Imunon Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 31, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-013850

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License